ORLANDO, FLA.—In children, adolescents and young adults with B-cell acute lymphoblastic leukemia (B-ALL) who have relapsed after initial therapy, the bispecific T-cell engager blinatumomab is being called a new standard of care. A phase 3 trial testing this therapy was stopped at an interim analysis because of an overall survival (OS) advantage over chemotherapy.
Compared with standard intensive chemotherapy regimen UKALLR3, blinatumomab (Blincyto, Amgen) increased the primary end